Alzheimer; News from the web:

“It is a very novel discovery showing that simply inhaling an inert gas can have such a profound neuroprotective effect,” said senior and co-corresponding author Oleg Butovsky, PhD and director of the lab where the research took place at Brigham and Women’s.

“One of the main limitations in the field of Alzheimer’s disease research and treatment is that it is extremely difficult to design medications that can pass the blood-brain barrier—but Xenon gas does. We look forward to seeing this novel approach tested in humans.”

Read all about it HERE

Alzheimer; News from the web:

Could key changes in intra-network connectivity revealed on brain magnetic resonance imaging (MRI) scans indicate the development of Alzheimer’s disease or Parkinson’s disease in patients with mild cognitive impairment (MCI)?

For a new study, recently published in Academic Radiology, researchers reviewed cognitive function assessments and resting-state functional MRI (fMRI) data for 33 patients who had MCI prior to Alzheimer’s disease (AD), 55 patients who had MCI prior to developing Parkinson’s disease (PD) and 34 healthy controls. The cognitive function assessments with the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were performed within one hour prior to fMRI, according to the study.

Read all about it HERE

Alzheimer; News from the web:

a new study in mice brings us one step closer to understanding what triggers the disease. The researchers have uncovered a specific enzyme that may be behind one of the key features of Alzheimer’s.

Read all about it HERE

Alzheimer; News from the web:

A team of international researchers, led by UC San Francisco, has completed the first large-scale study of posterior cortical atrophy, a baffling constellation of visuospatial symptoms that present as the first signs of Alzheimer’s disease. These symptoms occur in up to 10% of cases of Alzheimer’s disease.

Read all about it HERE

Alzheimer; News from the web:

Today, we are living history: the U.S. Food and Drug Administration (FDA) granted traditional approval of lecanemab, sold under the brand name Leqembi, for the treatment of early-stage Alzheimer’s disease. This is the first traditional approval granted for an Alzheimer’s treatment that changes the underlying course of the disease. Learn more here.

In addition, the Centers for Medicare & Medicaid Services (CMS) announced it will cover the treatment through Medicare. Read our statement here.

Read all about it HERE